Nitric oxide and endothelin in acute hypoxic pulmonary vasoconstriction and adaptation to chronic hypoxia.
Rumsey
W L
WL
Zeneca Pharmaceuticals, Wilmington, Delaware 19850-5437, USA.
Abbott
B M
BM
Bertelsen
D L
DL
DeSiato
M A
MA
D000064:Acclimatization; D000208:Acute Disease; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure; D000077300:Bosentan; D002908:Chronic Disease; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D000860:Hypoxia / Q000503:physiopathology*; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011651:Pulmonary Artery / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects
D000959:Antihypertensive Agents; D013449:Sulfonamides; D019001:Nitric Oxide Synthase; D000077300:Bosentan; D019331:NG-Nitroarginine Methyl Ester